TABLE 2.
Topics covered in online didactic course, clinical case workshop and national conference sessions.
| Online didactic course | Clinical case workshop | Conference sessions |
|---|---|---|
| • Introduction to the human genome and pharmacogenes | PGx cases in | • Economic value of PGx in clinical care |
| • Clinical PGx resources and CPIC guidelines | • Mental health | • Overcoming economic barriers in PGx |
| • How PGx pertains to genetic exceptionalism | • Cardiology | • Use of PGx in preventing harm |
| • PGx and health equity | • Pediatrics | • Costs of implementing health system-wide PGx |
| • PGx testing panels | • Oncology | • Buying versus building clinical decision support tools for PGx |
| • Educating patients in PGx | • Bone marrow transplant | • Payer perspectives on PGx |
| • Regulatory considerations of PGx | • NSAIDs | • Local coverage determinations for PGx testing and reimbursement |
| • ELSI and PGx | • Opioids | • Integrating medication therapy management/PGx in practice |
| • PGx clinical decision support | • Proton pump inhibitors | • Educating patients in PGx and return of results |
| • Implementation of PGx in health systems | • PGx assays and phenotype calls | • Challenges and solutions for PGx in rural and underserved populations |
| • PGx in cardiology | • CYP2D6 phenoconversion | • Updates to PGx guidelines for SNRIs and SSRIs, beta blockers, statins, NSAIDs and clopidogrel |
| • PGx in oncology | • Complex PGx associations/multiple drug-metabolizing genes and pharmacodynamic genes | |
| • PGx in pediatrics | • Regulatory issues relevant to PGx | |
| • PGx in psychiatry | • Developing telehealth for PGx | |
| • PGx in HLA | • Novel education and implementation strategies for PGx | |
| • PGx in NSAIDs | • Legal/liability implications of PGx for physicians and pharmacists | |
| • PGx in opioids | • Moving beyond Eurocentric PGx to improve health outcomes for all | |
| • PGx in proton pump inhibitors |